Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...
The field of oncology has seen significant advancements in understanding and treating various types of cancers. One such area is the study of Pulmonary Neuroendocrine Tumors (NETs), a rare and ...
Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results